Amicus Therapeutics, Inc. (FOLD) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Amicus Therapeutics, Inc. (FOLD) Bundle
Whether you’re an investor or an analyst, this (FOLD) DCF Calculator is your go-to resource for accurate valuation. Preloaded with real data from Amicus Therapeutics, Inc., you can adjust forecasts and instantly observe the effects.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 182.2 | 260.9 | 305.5 | 329.2 | 399.4 | 488.5 | 597.6 | 731.1 | 894.4 | 1,094.1 |
| Revenue Growth, % | 0 | 43.16 | 17.11 | 7.76 | 21.3 | 22.33 | 22.33 | 22.33 | 22.33 | 22.33 |
| EBITDA | -332.3 | -243.0 | -202.9 | -199.6 | -92.1 | -335.4 | -410.2 | -501.9 | -613.9 | -751.0 |
| EBITDA, % | -182.32 | -93.14 | -66.4 | -60.62 | -23.06 | -68.64 | -68.64 | -68.64 | -68.64 | -68.64 |
| Depreciation | 4.8 | 8.8 | 6.2 | 5.3 | 7.9 | 11.4 | 13.9 | 17.0 | 20.8 | 25.5 |
| Depreciation, % | 2.62 | 3.39 | 2.03 | 1.62 | 1.97 | 2.33 | 2.33 | 2.33 | 2.33 | 2.33 |
| EBIT | -337.0 | -251.8 | -209.1 | -204.9 | -100.0 | -344.2 | -421.0 | -515.0 | -630.1 | -770.8 |
| EBIT, % | -184.94 | -96.53 | -68.44 | -62.24 | -25.03 | -70.45 | -70.45 | -70.45 | -70.45 | -70.45 |
| Total Cash | 452.7 | 483.3 | 482.5 | 293.6 | 286.2 | 450.3 | 550.8 | 673.8 | 824.3 | 1,008.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 33.3 | 46.9 | 52.7 | 66.2 | 87.6 | 93.4 | 114.2 | 139.7 | 170.9 | 209.1 |
| Account Receivables, % | 18.26 | 17.99 | 17.24 | 20.11 | 21.94 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 |
| Inventories | 14.0 | 19.6 | 26.8 | 23.8 | 59.7 | 45.1 | 55.2 | 67.5 | 82.6 | 101.0 |
| Inventories, % | 7.7 | 7.5 | 8.78 | 7.23 | 14.95 | 9.23 | 9.23 | 9.23 | 9.23 | 9.23 |
| Accounts Payable | 21.7 | 17.1 | 21.5 | 15.4 | 15.1 | 33.2 | 40.6 | 49.7 | 60.8 | 74.3 |
| Accounts Payable, % | 11.92 | 6.54 | 7.04 | 4.68 | 3.79 | 6.79 | 6.79 | 6.79 | 6.79 | 6.79 |
| Capital Expenditure | -20.0 | -3.2 | -3.9 | -3.8 | -7.4 | -16.1 | -19.7 | -24.1 | -29.5 | -36.1 |
| Capital Expenditure, % | -10.98 | -1.24 | -1.27 | -1.14 | -1.86 | -3.3 | -3.3 | -3.3 | -3.3 | -3.3 |
| Tax Rate, % | -0.988 | -0.988 | -0.988 | -0.988 | -0.988 | -0.988 | -0.988 | -0.988 | -0.988 | -0.988 |
| EBITAT | -337.5 | -254.2 | -216.8 | -200.3 | -100.9 | -342.6 | -419.1 | -512.7 | -627.2 | -767.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -378.3 | -272.4 | -223.0 | -215.3 | -158.1 | -320.4 | -448.4 | -548.6 | -671.1 | -820.9 |
| WACC, % | 8.12 | 8.12 | 8.12 | 8.09 | 8.12 | 8.11 | 8.11 | 8.11 | 8.11 | 8.11 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2,161.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -837 | |||||||||
| Terminal Value | -13,699 | |||||||||
| Present Terminal Value | -9,275 | |||||||||
| Enterprise Value | -11,436 | |||||||||
| Net Debt | 198 | |||||||||
| Equity Value | -11,634 | |||||||||
| Diluted Shares Outstanding, MM | 295 | |||||||||
| Equity Value Per Share | -39.41 |
What You Will Get
- Real FOLD Financial Data: Pre-filled with Amicus Therapeutics’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Amicus Therapeutics’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Amicus Therapeutics, Inc. (FOLD).
- WACC Tool: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
- Customizable Forecast Assumptions: Adjust growth projections, capital expenditures, and discount rates to fit Amicus Therapeutics' strategy.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Amicus Therapeutics, Inc. (FOLD).
- Interactive Dashboard and Charts: Visual representations that encapsulate essential valuation metrics for streamlined analysis.
How It Works
- Download the Template: Gain immediate access to the Excel-based FOLD DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model will automatically refresh Amicus Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the outcomes to inform your investment or financial analysis.
Why Choose This Calculator for Amicus Therapeutics, Inc. (FOLD)?
- Accuracy: Utilizes real Amicus Therapeutics financial data for precise calculations.
- Flexibility: Allows users to easily adjust and test various input parameters.
- Time-Saving: Eliminates the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and attention to detail expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users with varying levels of financial modeling knowledge.
Who Should Use This Product?
- Investors: Accurately assess Amicus Therapeutics’ fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial analysis and reporting.
- Consultants: Efficiently modify the template for client valuation reports.
- Entrepreneurs: Acquire insights into financial modeling practices of leading biotech firms.
- Educators: Employ it as a teaching resource to illustrate valuation techniques.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations.
- Real-World Data: Amicus Therapeutics, Inc.'s (FOLD) historical and projected financials preloaded for analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to evaluate different scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables providing clear, actionable results.